Trump signs psychedelics order

The new executive order aims to ease regulatory barriers for scientists studying the therapeutic potential of substances like psilocybin, MDMA, and ibogaine.

Trump cited the need for innovative solutions to the nation's mental health crisis, particularly for veterans suffering from PTSD. FDA Commissioner Marty Makary hailed the decision as a 'historic moment' for medical science.

While some health experts have raised concerns about safety and oversight, the order has been welcomed by advocates who believe psychedelics could revolutionize the treatment of depression and addiction.